Long-term Safety and Efficacy Follow-up of BIIB111 for the Treatment of Choroideremia and BIIB112 for the Treatment of X-Linked Retinitis Pigmentosa
Launched by NIGHTSTARX LTD, A BIOGEN COMPANY · Jun 29, 2018
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
This study was previously posted by NightstaRx Ltd. In October 2020, sponsorship of the trial was transferred to Biogen.
Gender
MALE
Eligibility criteria
- Key Inclusion Criteria:
- • CHM Participants
- • a. Have participated in and exited from an interventional study that investigated the safety and efficacy of a sub-retinal injection of BIIB111 for CHM.
- • XLRP Participants
- • a. Have received a sub-retinal injection of BIIB112 for XLRP and have exited an antecedent study.
- Key Exclusion Criteria:
- • Participants are not eligible for study participation if they meet the following exclusion criterion.
- • a. In the opinion of the Investigator and/or the Sponsor, it is not in the participant's best interest to participate in the study.
- • NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
About Nightstarx Ltd, A Biogen Company
Nightstarx Ltd, a subsidiary of Biogen, is a pioneering biotechnology company focused on developing innovative gene therapies for rare inherited retinal diseases. Leveraging advanced scientific research and cutting-edge technology, Nightstarx aims to address significant unmet medical needs by offering transformative treatment options that can restore vision and improve the quality of life for patients. With a commitment to excellence and patient-centered care, Nightstarx collaborates with leading experts and institutions to advance its clinical programs and bring new hope to affected individuals and their families.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New York, New York, United States
Baltimore, Maryland, United States
Miami, Florida, United States
Helsinki, , Finland
Oxford, , United Kingdom
Bonn, , Germany
Oxford, , United Kingdom
Southampton, , United Kingdom
Tübingen, , Germany
Portland, Oregon, United States
Nijmegen, , Netherlands
New York, New York, United States
Manchester, , United Kingdom
Miami, Florida, United States
Montpellier, , France
Glostrup, , Denmark
London, , United Kingdom
Gainesville, Florida, United States
Nijmegen, , Netherlands
Southampton, , United Kingdom
Montpellier, , France
Edmonton, Alberta, Canada
Bonn, , Germany
London, , United Kingdom
Los Angeles, California, United States
Baltimore, Maryland, United States
Boston, Massachusetts, United States
Cincinnati, Ohio, United States
Dallas, Texas, United States
Madison, Wisconsin, United States
Vancouver, British Columbia, Canada
Montreal, Quebec, Canada
Gainesville, Florida, United States
Sao Paulo, , Brazil
Los Angeles, California, United States
Boston, Massachusetts, United States
Cincinnati, Ohio, United States
Portland, Oregon, United States
Dallas, Texas, United States
Madison, Wisconsin, United States
Edmonton, Alberta, Canada
Vancouver, British Columbia, Canada
Montreal, Quebec, Canada
Glostrup, , Denmark
Helsinki, , Finland
Paris, , France
Tübingen, , Germany
Manchester, , United Kingdom
Patients applied
Trial Officials
Medical Director
Study Director
Biogen
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials